A notable advancement in diabetes care is emerging with the introduction of tirzepatide at a dosage of 45mg. This new version builds upon the existing success of tirzepatide, a dual GIP and GLP-1 agonist, and offers a https://utherpeptidess.com/product/tirzepatide-45mg/